|Bid||0.00 x 4000|
|Ask||0.00 x 900|
|Day's Range||15.21 - 16.83|
|52 Week Range||12.24 - 28.06|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.13|
Subscribe to Yahoo Finance Plus to view Fair Value for ACAD
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients. Initial data announced in April showed that the primary endpoint of pain intensity was not met. Rival Vertex boasted a mid-phase win for a similar candidate. Acadia has also discontinued ACP-319, which w
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?